Key considerations during the transition from the acute phase of the COVID-19 pandemic: a narrative review

P Rzymski, M Pokorska-Śpiewak, T Jackowska… - Vaccines, 2023 - mdpi.com
The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …

[HTML][HTML] A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies

CX Li, S Noreen, LX Zhang, M Saeed, PF Wu… - Biomedicine & …, 2022 - Elsevier
Coronavirus is a family of viruses that can cause diseases such as the common cold, severe
acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS). The …

Landscape and progress of global COVID-19 vaccine development

HY Huang, SH Wang, Y Tang, W Sheng… - Human Vaccines & …, 2021 - Taylor & Francis
The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has
affected billions of lives globally, and the world hopes to end this epidemic by effective …

[HTML][HTML] COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development

R Singh, A Kang, X Luo, M Jeyanathan… - The FASEB …, 2021 - ncbi.nlm.nih.gov
The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a
century. In 11 months since its first emergence, according to WHO, the causative infectious …

[HTML][HTML] COVID-19 challenges and its therapeutics

SU Rehman, SU Rehman, HH Yoo - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Abstract COVID-19, an infectious disease, has emerged as one of the leading causes of
death worldwide, making it one of the severe public health issues in recent decades. nCoV …

Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?

G Joshi, P Borah, S Thakur, P Sharma… - Human Vaccines & …, 2021 - Taylor & Francis
ABSTRACT As of September 2021, 117 COVID-19 vaccines are in clinical development,
and 194 are in preclinical development as per the World Health Organization (WHO) …

Clinical course and management of COVID-19 in the era of widespread population immunity

EA Meyerowitz, J Scott, A Richterman, V Male… - Nature Reviews …, 2024 - nature.com
The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

Efficacy and safety of COVID-19 vaccines—an update

E Sharma, S Revinipati, S Bhandari, S Thakur, S Goyal… - Diseases, 2022 - mdpi.com
A few centuries ago, the first vaccine vial was formulated, and since then, they have resulted
in an eminent reduction in infectious diseases associated morbidity and mortality. The …

COVID-19 vaccine booster: to boost or not to boost

R Shekhar, I Garg, S Pal, S Kottewar… - Infectious disease …, 2021 - mdpi.com
Developing safe and effective vaccines against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) at a breakneck speed has been an exceptional human …

[HTML][HTML] From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era

G Miao, Z Chen, H Cao, W Wu, X Chu, H Liu… - Biomedicine & …, 2023 - Elsevier
The COVID-19 pandemic has affected millions of people and posed an unprecedented
burden on healthcare systems and economies worldwide since the outbreak of the COVID …